AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.